Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2015 from OUS - Translational studies with a special focus on pancreatic cancer
9 publications found
High ABCC2 and low ABCG2 gene expression are early events in the colorectal adenoma-carcinoma sequence
PLoS One, 10 (3), e0119255
DOI 10.1371/journal.pone.0119255, PubMed 25793771
Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma
HPB (Oxford), 18 (3), 247-54
DOI 10.1016/j.hpb.2015.09.004, PubMed 27017164
Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis
Mol Oncol, 10 (2), 330-43
DOI 10.1016/j.molonc.2015.10.021, PubMed 26601720
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Nat Cell Biol, 17 (6), 816-26
DOI 10.1038/ncb3169, PubMed 25985394
Serum N-Glycome Characterization in Patients with Resectable Periampullary Adenocarcinoma
J Proteome Res, 14 (12), 5144-56
DOI 10.1021/acs.jproteome.5b00395, PubMed 26515733
Tumour exosome integrins determine organotropic metastasis
Nature, 527 (7578), 329-35
DOI 10.1038/nature15756, PubMed 26524530
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin
Pharmacogenomics J, 16 (3), 272-9
DOI 10.1038/tpj.2015.54, PubMed 26261061
Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study
Acta Oncol, 55 (3), 265-77
DOI 10.3109/0284186X.2015.1068445, PubMed 26213211
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma
Mol Oncol, 10 (2), 303-16
DOI 10.1016/j.molonc.2015.10.011, PubMed 26590090